SLGL (SLGL) Stock Price & Analysis
SLGL (SLGL) fell 4.72% to USD 76.22 as of June 10, 2026 at 09:34 UTC, according to Nexqual real-time market data.
SLGL last closed at USD 80; the session ranged USD 73.04–80.99 on volume of 41,498 shares. Market capitalization is $249.16M, with a 52-week range of USD 6.85–97.97 (NCM). Source: Nexqual, June 10, 2026 at 09:34 UTC.
Key Statistics (as of June 10, 2026 at 09:34 UTC)
| Price | USD 76.22 |
|---|---|
| Change | ▼ 4.72% (down) |
| Previous Close | USD 80 |
| Open | USD 80.98 |
| Day Range | USD 73.04 – 80.99 |
| 52-Week Range | USD 6.85 – 97.97 |
| Volume | 41,498 shares |
| Market Cap | $249.16M |
| Exchange | NCM |
Technical Analysis (SLGL)
Nexqual's technical model rates SLGL "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 09:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.4 (neutral) |
| vs SMA50 | Above (USD 73.49) |
| MACD | 0.98 (positive) |
Analyst Ratings (SLGL)
Wall Street analysts rate SLGL "Strong Buy" based on 2 analysts, with a mean price target of USD 147 (range USD 110–184), per Nexqual as of June 10, 2026 at 09:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 147 |
| High Target | USD 184 |
| Low Target | USD 110 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (SLGL)
| Next Earnings Date | 2026-08-21 |
|---|---|
| EPS Estimate | USD -3.33 |
| Revenue Estimate | $1.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.31 vs est -2.86 ▲ beat |
| 2025-12-31 | USD -1.06 vs est 0.39 ▼ miss |
| 2025-09-30 | USD -2.13 vs est -2.09 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:34 UTC.
Financials & Fundamentals (SLGL)
| Total Revenue | $18.46M |
|---|---|
| Revenue Growth (YoY) | -89.50% |
| Gross Margin | +9.30% |
| Operating Margin | -3569.44% |
| Profit Margin | -5.66% |
| ROE | -2.92% |
| Debt / Equity | 1.68 |
| Current Ratio | 8.84 |
| Total Cash | $52.83M |
| Total Debt | $862,000 |
Source: Nexqual, June 10, 2026 at 09:34 UTC.
Financial Health Score (SLGL)
Nexqual rates SLGL's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:34 UTC.
| Growth | Critical — Revenue -90% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $53M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -3%, ROA -3.5% |
Ownership (SLGL)
| Insider Ownership | +59.70% |
|---|---|
| Institutional Ownership | +43.23% |
| Shares Outstanding | 3.27M |
| Float | 533,990 |
| Short % of Float | +5.04% |
Source: Nexqual, June 10, 2026 at 09:34 UTC.
Leadership (SLGL)
SLGL is led by Moshe Arkin (age 72), CEO & Executive Chairman, per Nexqual as of June 10, 2026 at 09:34 UTC.
| CEO & Executive Chairman | Moshe Arkin (age 72) |
|---|---|
| Chief Financial Officer | Eyal Ben-Or (age 41) |
| Chief Operating Officer | Itzik Yosef (age 49) |
Major Backers & Investors (SLGL)
Notable institutional backers of SLGL include Opaleye Management Inc., Great Point Partners LLC, Phoenix Financial Ltd., according to Nexqual as of June 10, 2026 at 09:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 17.79% |
| Great Point Partners LLC | 9.76% |
| Phoenix Financial Ltd. | 7.5% |
| Trails Edge Capital Partners, LP | 3.04% |
| Citadel | 1.32% |
| Affinity Asset Advisors, Llc | 1.25% |
| Squadron Capital Management LLC | 1.1% |
| Stonepine Capital Management, LLC | 0.99% |
Source: Nexqual, June 10, 2026 at 09:34 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | USD 6.12 | ▲ 1.32% |
| STRO | Sutro Biopharma, Inc. | USD 25.79 | ▼ 1.15% |
| URGN | UroGen Pharma Ltd. | USD 28.18 | ▲ 4.95% |
| MDWD | MediWound Ltd. | USD 14.3 | ▲ 0.85% |
| SYBX | Synlogic, Inc. | USD 0.64 | ▼ 7.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:34 UTC. This page is informational and not investment advice.